Milestone Pharmaceuticals (MIST) Other Non-Current Liabilities (2020 - 2026)

Milestone Pharmaceuticals' Other Non-Current Liabilities history runs 7 years deep, the most recent figure standing at $55.6 million for Q1 2026.

• Quarterly Other Non-Current Liabilities rose 4.85% year-over-year to $55.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $55.6 million (up 4.85% YoY) and the FY2025 annual result came in at $83000.0, down 99.84% from the prior year.
• Other Non-Current Liabilities was $55.6 million for Q1 2026 at Milestone Pharmaceuticals, up from $83000.0 in the prior quarter.
• Across five years, Other Non-Current Liabilities topped out at $55.6 million in Q3 2025 and bottomed at $83000.0 in Q4 2025.
• A 5-year average of $48.0 million and a median of $52.9 million in 2022 frame the typical range for Other Non-Current Liabilities.
• Annual changes were most pronounced in 2023 — Other Non-Current Liabilities surged 41.07% — and 2025, when it plunged 99.84%.
• Milestone Pharmaceuticals' Other Non-Current Liabilities stood at $34.4 million in 2022, then jumped by 41.07% to $48.5 million in 2023, then rose by 9.53% to $53.1 million in 2024, then plunged by 99.84% to $83000.0 in 2025, then surged by 66946.99% to $55.6 million in 2026.
• Business Quant data shows MIST's Other Non-Current Liabilities at $55.6 million in Q1 2026, $83000.0 in Q4 2025, and $55.6 million in Q3 2025.